跳至主要内容
临床试验/NCT06612697
NCT06612697进行中(未招募)不适用

Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone

Taichung Veterans General Hospital1 个研究点 分布在 1 个国家目标入组 262 人开始时间: 2023年10月2日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
262
试验地点
1
主要终点
Overall Survival

研究概览

简要总结

Nasopharyngeal carcinoma (NPC) is a malignant tumor primarily originating in the nasopharynx, commonly found in populations in southern China, certain regions of Asia, and North Africa. The main treatment for NPC is primarily radiotherapy, with some patients receiving combined chemotherapy. Early-stage NPC patients can achieve adequate tumor control with radiation therapy alone. Various studies report that the 5-year survival rate for very early-stage NPC exceeds 90%. However, some stage I patients experience local recurrence or distant metastasis after treatment, indicating treatment failure. This study aims to retrospectively analyze the factors contributing to treatment failure and prognostic factors in this group of early-stage NPC patients.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with nasopharyngeal carcinoma based on endoscopic pathological reports.
  • Included early-stage patients classified as cT1-2, cN0-1, M
  • Had baseline imaging (CT or MRI) prior to treatment.
  • Received definitive radiotherapy at our institution and had long-term follow-up with complete medical records.

排除标准

  • Excluded from the study are patients with local lymph node metastasis or distant metastasis (cN ≥ 2, M = 1) as determined by imaging studies.
  • Patients who did not receive definitive radiotherapy at our institution or had incomplete medical records during long-term follow-up are also excluded.
  • Patients diagnosed with any other primary cancer within five years prior to the diagnosis of nasopharyngeal carcinoma (excluding DCIS and skin cancer) are excluded from the study.

结局指标

主要结局

Overall Survival

时间窗: The 5-year survival rate after surgery

Overall survival is an important indicator for assessing treatment efficacy, reflecting the impact of treatment on extending patient life. It is typically calculated by measuring the time from the start of treatment until the patient's death or loss to follow-up.

Disease-Free Survival

时间窗: Within 5 years after surgery

Disease-free survival (DFS) refers to the period during which a patient remains free of disease recurrence following treatment. This indicator helps evaluate the effectiveness of the treatment, particularly in early-stage cancer patients, as it reflects the durability of tumor control. DFS is typically calculated by measuring the time from the end of treatment to the first occurrence of disease recurrence.

Local Control Rate

时间窗: Within 5 years after surgery

Local control rate refers to the effectiveness of treatment in managing the tumor at its primary site, reflecting the ability to prevent local recurrence. A high local control rate indicates that the treatment has successfully eradicated the tumor or effectively suppressed its growth, which is crucial for the prognosis of tumors such as nasopharyngeal carcinoma.

次要结局

  • Recurrence Rate(Within 5 years after surgery)
  • Metastasis Rate(Within 5 years after surgery)
  • Treatment-Related Adverse Events(Within 5 years after surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验